<DOC>
	<DOCNO>NCT02400190</DOCNO>
	<brief_summary>This study collect rate local/regional recurrence select patient receive radiation treatment lumpectomy surgery . These woman must postmenopausal ; hormone receptor-positive , Her2-negative tumor ; Oncotype-DX RS less equal 18 ; plan receive endocrine therapy . In way , study seek collect prospective data support idea population sufficiently low risk local/regional recurrence omission adjuvant radiation might reasonable option .</brief_summary>
	<brief_title>The IDEA Study ( Individualized Decisions Endocrine Therapy Alone )</brief_title>
	<detailed_description>This study 's primary aim determine rate recurrence innovative approach consider tumor biology select patient may avoid radiation , restriction eligibility woman age 50-69 hormone-sensitive , Her2-negative tumor Oncotype-DX RS ≤ 18 plan receive endocrine therapy . In way , study seek collect prospective data support idea population low risk LRR omission adjuvant radiation reasonable .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Postmenopausal status , define ( ) patient age 60 great , , ( b ) patient age 5069 either ( ) s/p bilateral oophorectomy , , ( b ) intact uterus without menses past 12 month , , ( c ) biochemical confirmation postmenopausal status . Histopathological confirmation Stage 1 ( pT1N0M0 ) invasive breast cancer status post breast conserving surgery Negative axillary node ( isolated tumor cell cluster measure &gt; 0.2mm allow ) Allowable option axillary stag include : Sentinel node biopsy Sentinel node biopsy follow axillary dissection Axillary dissection Margins excision ≥2mm ER+ , PR+ , Her2 use current College American Pathologists guideline OncotypeDX RS ≤ 18 Disease must unifocal clinical , radiologic , pathologic examination Registration within 90 day last surgical procedure breast cancer treatment Patient must willingly sign study specific informed consent prior study entry Patient must candidate willing take endocrine therapy minimum 5 year ( aromatase inhibitor tamoxifen ) . Patients already begin endocrine therapy lumpectomy eligible . Patient must bilateral mammogram within 120 day study entry . Patient must Zubrod performance status 02 Evidence multifocal multicentric breast cancer biopsyproven negative . Note MRI require study , perform , evidence disease beyond site primary tumor ipsilateral breast contralateral breast must biopsyproven malignant registration . Metastatic disease . Note specific stag study mandate , study perform must provide clear evidence metastatic spread . Previous radiation therapy breast region Prior DCIS invasive breast cancer Bilateral breast cancer Prior nonbreast invasive malignancy nonmelanoma skin cancer , unless evidence disease least 5 year Known carrier mutation know predispose towards breast cancer development ( include BRCA1 BRCA2 ) . Note : test mutation status require protocol ; criterion apply patient test know carrier status .</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>radiation</keyword>
	<keyword>lumpectomy</keyword>
	<keyword>favorable biology</keyword>
	<keyword>omission</keyword>
</DOC>